The effects of transdermal oestradiol and oral progestogens on haemostasis variables

被引:26
作者
Kroon, UB
Tengborn, L
Rita, H
Backstrom, AC
机构
[1] SAHLGRENS UNIV HOSP,DEPT MED 2,COAGULAT CTR,S-41345 GOTHENBURG,SWEDEN
[2] ORION PHARMA,ORION CORP,ESPOO,FINLAND
[3] SAHLGRENS UNIV HOSP,DEPT OBSTET & GYNECOL,S-41345 GOTHENBURG,SWEDEN
来源
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 1997年 / 104卷
关键词
D O I
10.1111/j.1471-0528.1997.tb11565.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the effects of 1 g (1 mg oestradiol) transdermal oestradiol gel continuously combined with 10 mg medroxyprogesterone acetate orally 12 days either monthly or every third month on haemostasis variables. Design An open, parallel stratified study. Setting Sahlgrenska University Hospital, Goteborg, Sweden Participants A total of 48 peri- and postmenopausal women less than 65 years of age participated in this study. Twenty-seven women, who had from 2 months to 3 years since their last period were included in group I. Twenty-one women, who were more than 3 years postmenopausal, comprised group II. Main outcome measures The following parameters were determined: von Willebrand factor antigen, factor VII antigen, fibrinogen, antithrombin, protein C, protein S, plasminogen activator inhibitor activity, tissue plasminogen activator antigen, prothrombin fragment(1+2), thrombin-antithrombin complex and platelets. Results Both regimens decreased fibrinogen, factor VII antigen as well as antithrombin. Conclusions These changes were mainly 'in an anti-thrombotic direction'. The overall impression is that the transdermally administered oestrogen in combination with an oral progestogen induced favourable, although slight changes in the haemostatic system. The possible influence of these changes on the risk of cardiovascular disease remains yet to be studied.
引用
收藏
页码:32 / 37
页数:6
相关论文
共 21 条
[1]  
AYLWARD M, 1978, POSTGRAD MED J, V54, P31
[2]  
Beller F K, 1985, Obstet Gynecol Surv, V40, P425, DOI 10.1097/00006254-198507000-00003
[3]   COAGULATION EFFECTS OF ORAL CONTRACEPTION [J].
BONNAR, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 157 (04) :1042-1048
[4]   CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].
BUSH, TL ;
BARRETTCONNOR, E ;
COWAN, LD ;
CRIQUI, MH ;
WALLACE, RB ;
SUCHINDRAN, CM ;
TYROLER, HA ;
RIFKIND, BM .
CIRCULATION, 1987, 75 (06) :1102-1109
[5]  
CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392
[6]  
CONARD J, 1983, THROMB HAEMOSTASIS, V49, P245
[7]   A NOVEL FORM OF FACTOR-VII IN PLASMA FROM MEN AT RISK FOR CARDIOVASCULAR-DISEASE [J].
DALAKER, K ;
HJERMANN, I ;
PRYDZ, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (02) :315-322
[8]   FACTOR-VII HYPERACTIVITY IN ACUTE MYOCARDIAL THROMBOSIS - A RELATION TO THE COAGULATION ACTIVATION [J].
DESOUSA, JC ;
AZEVEDO, J ;
SORIA, C ;
BARROS, F ;
RIBEIRO, C ;
PARREIRA, F ;
CAEN, JP .
THROMBOSIS RESEARCH, 1988, 51 (02) :165-173
[9]  
EDZARD E, 1993, ANN INTERN MED, V118, P956
[10]   CORRELATION OF FACTOR-VII ACTIVITY AND ANTIGEN WITH CHOLESTEROL AND TRIGLYCERIDES IN HEALTHY-YOUNG ADULTS [J].
HOFFMAN, CJ ;
MILLER, RH ;
HULTIN, MB .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (03) :267-270